Talaris Therapeutics (TALS) Insider Trading & Ownership → This TSLA short trade is on a nine win hot streak (From WealthPress) (Ad) Free TALS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Insider TradesStock AnalysisCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipTrendsStock AnalysisCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipTrends Talaris Therapeutics (NASDAQ:TALS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage16.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)1Amount OfInsider Selling(Last 12 Months)$377,686.61 TALS Insider Buying and Selling by Quarter Ad WealthPressThis indicator is great for calling bottoms“It was designed to help boost your chances of finding rock solid trade ideas” It’s called the “Master Indicator” And it’s quite possibly one of the most useful indicators you’ll ever use.If you’d like to join me just follow this link here. Talaris Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails6/14/2023Suzanne IldstadDirectorSell12,942$2.49$32,225.58 6/12/2023Suzanne IldstadDirectorSell16,870$2.59$43,693.30 6/9/2023Suzanne IldstadDirectorSell25,419$2.46$62,530.74 6/7/2023Suzanne IldstadDirectorSell75,001$2.39$179,252.39 6/5/2023Suzanne IldstadDirectorSell7,841$2.52$19,759.32 6/1/2023Suzanne IldstadDirectorSell15,713$2.56$40,225.28 (Data available from 1/1/2013 forward) TALS Insider Trading Activity - Frequently Asked Questions Who is on Talaris Therapeutics's Insider Roster? The list of insiders at Talaris Therapeutics includes Francois Nader, Scott Requadt, and Suzanne Ildstad. Learn more on insiders at TALS. What percentage of Talaris Therapeutics stock is owned by insiders? 16.50% of Talaris Therapeutics stock is owned by insiders. Learn more on TALS's insider holdings. Which Talaris Therapeutics insiders have been buying company stock? The following insiders have purchased TALS shares in the last 24 months: Francois Nader ($311,780.00), and Scott Requadt ($71,986.22). How much insider buying is happening at Talaris Therapeutics? Insiders have purchased a total of 104,562 TALS shares in the last 24 months for a total of $383,766.22 bought. Which Talaris Therapeutics insiders have been selling company stock? The following insider sold TALS shares in the last 24 months: Suzanne Ildstad ($2,178,229.38). How much insider selling is happening at Talaris Therapeutics? Insiders have sold a total of 832,218 Talaris Therapeutics shares in the last 24 months for a total of $2,178,229.38 sold. More Insider Trading Tools from MarketBeat Related Companies: Fulcrum Therapeutics Insider Trades Nautilus Biotechnology Insider Trades BioAtla Insider Trades Cara Therapeutics Insider Trades ADMA Biologics Insider Trades Novavax Insider Trades CG Oncology Insider Trades Recursion Pharmaceuticals Insider Trades Kymera Therapeutics Insider Trades Beam Therapeutics Insider Trades Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: 3 Stocks Insiders are Buying That Should be on Your RadarInsider Trading is Good News for These Stocks4 Small-Cap Energy Stocks Insiders are Buying 3 Penny Stocks That Insiders Are BuyingThe 3 Hottest Insiders Buys This Month This page (NASDAQ:TALS) was last updated on 5/31/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarBiden Nomination CANCELED?The Freeport SocietyThis unknown company solves the biggest issue with AIManward PressDo This Before July 30 2024 To Claim Trump’s Gift Wealthpin ProA once-in-a-century profit opportunity?Digital Mavericks MediaMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryElon’s New A.I. Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist My Default Watchlist Adding Talaris Therapeutics, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.